A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Insmed
- 12 Jul 2024 Planned End Date changed from 31 Mar 2024 to 31 Jul 2025.
- 12 Jul 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Jul 2025.
- 09 May 2024 According to an Insmed media release, more than half of the target enrollment currently completed in this trial. Topline results from the Phase 2 PAH study continue to be expected in 2025.